Related Experiment Video
Updated: Apr 26, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.3K
The vitamin d dose response in obesity.
Ruban Dhaliwal1, Mageda Mikhail1, Martin Feuerman1
1Bone Mineral Research Center, Winthrop University Hospital, Mineola, New York.
Summary
Obese individuals show a lower vitamin D3 response. They may need 40% more vitamin D to reach optimal serum 25-hydroxyvitamin D levels compared to non-obese individuals.
Area of Science:
- Endocrinology
- Nutritional Science
- Public Health
Background:
- Vitamin D inadequacy is prevalent in obese populations.
- Understanding vitamin D3 metabolism in obesity is crucial for public health.
- Obesity may alter vitamin D bioavailability and efficacy.
Purpose of the Study:
- To determine the dose-response relationship of vitamin D3 supplementation in obese individuals.
- To compare vitamin D3 efficacy in obese versus non-obese populations.
- To establish optimal vitamin D intake recommendations for individuals with obesity.
Main Methods:
- Randomized, double-blind, placebo-controlled trial.
- Extension of a previous study on vitamin D dosing in healthy adults.
- Participants received daily vitamin D3 (100 μg or 50 μg) or placebo based on baseline 25-hydroxyvitamin D (25[OH]D) levels.
Main Results:
- The mean serum 25(OH)D concentration increased to 75 nmol/L in the active treatment group after 2 months.
- The mean vitamin D3 dose-response slope in obese subjects was 0.398 nmol/L/μg/day.
- This represents a significantly lower response compared to healthy subjects in a prior study.
Conclusions:
- Obese individuals exhibit a blunted dose-response to vitamin D3 supplementation.
- A 40% higher vitamin D intake may be necessary for obese individuals to achieve similar serum 25(OH)D levels as non-obese individuals.
- These findings have implications for vitamin D supplementation guidelines in obesity management.
Related Concept Videos
01:21Drug Dosing: Obese Patients
364
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364
01:23Role of Skin in Vitamin D Synthesis
7.9K
The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
7.9K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:03Dose-Response Relationship: Overview
5.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.1K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
437
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324